Another influential voice takes Bristol-Myers’ top execs to task as they scramble to shore up the big Celgene buyout
Brad Loncar is not a big fan of the executive teams at either Bristol-Myers Squibb or Celgene.
Today, as Bristol-Myers scrambled to win investors’ backing, the Loncar Cancer Immunotherapy ETF outlined why it would line up with the growing — though still marginal — opposition that has gathered around the mega-buyout since Wellington, with 8% of Bristol’s shares, said it would be voting against the deal. Loncar joins the activists at Starboard Value who have planted their flag with the rebellion.
Basic subscription required
Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.